BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...Myers as CMO. Greenleaf is CEO of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP). Bryan joins from UroGen...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

...at Bristol Myers Squibb Co. (NYSE:BMY).Peter Pfreundschuh joined degenerative disease company Frequency Therapeutics Inc. (NASDAQ:FREQ) as CFO. He was CFO at UroGen...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...FDA approves first therapy for urothelial cancer subtype FDA approved Jelmyto mitomycin gel from UroGen...
...Generic), Ontruzant (Other) Samsung Bioepis Co. Ltd. Merck & Co. Inc. Madrigal Pharmaceuticals Inc. Leo Pharma A/S Novartis AG TScan Therapeutics Inc. UroGen...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) (see “Roivant Pockets $3B from Dainippon” ). UroGen...
...Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:WVE) 1/24/19 $150.1 $1,268.3 $893.8 -30% Bellerophon Therapeutics Inc. (NASDAQ:BLPH) 1/23/19 $7.0 $48.1 $41.3 -14% UroGen...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Pharmaceutical Inc. (NASDAQ:RARE) Triheptanoin (UX007) Treat long-chain fatty acid oxidation disorders (LC-FAOD) Submit NDA Mid-2019 UroGen...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...Novartis Oncology after only 11 months on the job, to become president and CEO of Urogen...
...Munich, Germany Spark Therapeutics Inc. (NASDAQ:ONCE), Philadelphia, Pa. Takeda Pharmaceutical Co. Ltd. (JASDAQ:4502), Tokyo, Japan UroGen...
BioCentury | Jan 25, 2019
Financial News

UroGen, Wave each raise $150M follow-ons

...NASDAQ:URGN) and Wave Life Sciences Ltd. (NASDAQ:WVE) each raised $150 million in follow-ons. Uro-oncology company UroGen...
...Steps in as CEO, UroGen Reports 57% Complete Response Rate for Urothelial Cancer Therapy" ). UroGen...
...UroGen Pharma Ltd. (NASDAQ:URGN), Ra'anana, Israel Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass. Chris Lieu suvodirsen (WVE-210201) UGN-101 (mitogel) UroGen...
BioCentury | Jan 24, 2019
Financial News

UroGen, Wave each raise $150M follow-ons

...NASDAQ:URGN) and Wave Life Sciences Ltd. (NASDAQ:WVE) each raised $150 million in follow-ons. Uro-oncology company UroGen...
...the company's close of $53.66 on Tuesday, when it proposed the offering after market hours. UroGen...
...Steps in as CEO, UroGen Reports 57% Complete Response Rate for Urothelial Cancer Therapy" ). UroGen...
BioCentury | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

...appointed Elizabeth Barrett and George Golumbeski to its board. Barrett became president and CEO of UroGen...
Items per page:
1 - 10 of 73
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...Myers as CMO. Greenleaf is CEO of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH; TSX:AUP). Bryan joins from UroGen...
BioCentury | Dec 3, 2020
Management Tracks

Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA

...at Bristol Myers Squibb Co. (NYSE:BMY).Peter Pfreundschuh joined degenerative disease company Frequency Therapeutics Inc. (NASDAQ:FREQ) as CFO. He was CFO at UroGen...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

...FDA approves first therapy for urothelial cancer subtype FDA approved Jelmyto mitomycin gel from UroGen...
...Generic), Ontruzant (Other) Samsung Bioepis Co. Ltd. Merck & Co. Inc. Madrigal Pharmaceuticals Inc. Leo Pharma A/S Novartis AG TScan Therapeutics Inc. UroGen...
BioCentury | Mar 28, 2020
Management Tracks

Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more

...subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) (see “Roivant Pockets $3B from Dainippon” ). UroGen...
...Inc. Recursion Pharmaceuticals Inc. 89bio Inc. Heptares Therapeutics Ltd. Sosei Group Corp. Fusion Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...NASDAQ:WVE) 1/24/19 $150.1 $1,268.3 $893.8 -30% Bellerophon Therapeutics Inc. (NASDAQ:BLPH) 1/23/19 $7.0 $48.1 $41.3 -14% UroGen...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...Pharmaceutical Inc. (NASDAQ:RARE) Triheptanoin (UX007) Treat long-chain fatty acid oxidation disorders (LC-FAOD) Submit NDA Mid-2019 UroGen...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...Novartis Oncology after only 11 months on the job, to become president and CEO of Urogen...
...Munich, Germany Spark Therapeutics Inc. (NASDAQ:ONCE), Philadelphia, Pa. Takeda Pharmaceutical Co. Ltd. (JASDAQ:4502), Tokyo, Japan UroGen...
BioCentury | Jan 25, 2019
Financial News

UroGen, Wave each raise $150M follow-ons

...NASDAQ:URGN) and Wave Life Sciences Ltd. (NASDAQ:WVE) each raised $150 million in follow-ons. Uro-oncology company UroGen...
...Steps in as CEO, UroGen Reports 57% Complete Response Rate for Urothelial Cancer Therapy" ). UroGen...
...UroGen Pharma Ltd. (NASDAQ:URGN), Ra'anana, Israel Wave Life Sciences Ltd. (NASDAQ:WVE), Cambridge, Mass. Chris Lieu suvodirsen (WVE-210201) UGN-101 (mitogel) UroGen...
BioCentury | Jan 24, 2019
Financial News

UroGen, Wave each raise $150M follow-ons

...NASDAQ:URGN) and Wave Life Sciences Ltd. (NASDAQ:WVE) each raised $150 million in follow-ons. Uro-oncology company UroGen...
...the company's close of $53.66 on Tuesday, when it proposed the offering after market hours. UroGen...
...Steps in as CEO, UroGen Reports 57% Complete Response Rate for Urothelial Cancer Therapy" ). UroGen...
BioCentury | Jan 23, 2019
Company News

Management tracks: Cabaletta, Sage, MyoKardia

...appointed Elizabeth Barrett and George Golumbeski to its board. Barrett became president and CEO of UroGen...
Items per page:
1 - 10 of 73